Advertisement

Fabry Disease pp 181-187 | Cite as

Clinical Manifestations of Fabry Disease: An Overview

  • Atul MehtaEmail author
Chapter

Abstract

The last decade has seen an enormous expansion of interest in Fabry disease. The spectrum of clinical manifestations has been outlined in studies from single institutions and these observations have been confirmed and extended by publications from the registries which are associated with the two licensed forms of enzyme replacement therapy. It has become clear that Fabry disease, particularly atypical forms associated with residual enzyme activity, is much commoner that previously thought. Estimates range from 1:5,000 to 1:30,000. Fabry disease frequently presents as a stroke or isolated left ventricular hypertrophy. Skin manifestations appear to correlate well with overall disease severity. Some genotype/phenotype correlations have been demonstrated such that patients with miss- sense mutations generally have less severe clinical manifestations at a given age than patients with non-sense mutations. There is a very high prevalence of symptoms and clinical manifestations amongst females with Fabry disease. There is preliminary evidence that enzyme replacement therapy may be altering the natural history of the disease.

Keywords

Fabry disease Genotype/phenotype Stroke Enzyme replacement therapy Left-ventricular hypertrophy FOS Fabry registry 

References

  1. 1.
    Mehta A (2009) Anderson Fabry Disease: developments in diagnosis and treatment. Int J Clin Pharmacol Ther 47(Suppl 1):S66–S74PubMedGoogle Scholar
  2. 2.
    Anderson W (1898) A case of angiokeratoma. Br J Dermatol 18:113–117CrossRefGoogle Scholar
  3. 3.
    Fabry J (1898) Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syph 43:187–200Google Scholar
  4. 4.
    MacDermot KD, Holmes A, Miners AH (2001) Anderson Fabry disease clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760PubMedCrossRefGoogle Scholar
  5. 5.
    MacDermot KD, Holmes A, Miners AH (2001) Anderson Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate female carriers. J Med Genet 38:769–775PubMedCrossRefGoogle Scholar
  6. 6.
    Garboczi DN, Garman SC (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337(2):319–335PubMedCrossRefGoogle Scholar
  7. 7.
    Henter JI, Schieppatti A (2008) Why rare diseases are an important medical and social issue. Lancet 371:2039–2041PubMedCrossRefGoogle Scholar
  8. 8.
    Meikle PJ, Hopwood JJ, Clague AE et al (1999) Prevalence of lysosomal storage disorders. JAMA 281(3):249–254PubMedCrossRefGoogle Scholar
  9. 9.
    Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105(1–2):151–156PubMedGoogle Scholar
  10. 10.
    Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40PubMedCrossRefGoogle Scholar
  11. 11.
    Sachdev B, Takenaka T, Teraguchi H (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407–1411PubMedCrossRefGoogle Scholar
  12. 12.
    Monserrat L, Gimeno-Blanes JR, Marin F et al (2007) Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 50(25):2399–2403PubMedCrossRefGoogle Scholar
  13. 13.
    Rolfs A, Bottcher T, Zschiesche M et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366(9499):1794–1796PubMedCrossRefGoogle Scholar
  14. 14.
    Kotanko P, Kramer R, Devrnja D et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15(5):1323–1329PubMedCrossRefGoogle Scholar
  15. 15.
    Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236–242PubMedCrossRefGoogle Scholar
  16. 16.
    Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30(2):184–192PubMedCrossRefGoogle Scholar
  17. 17.
    Deegan PB, Baehner AF, Hughes DA et al (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43(4):347–352PubMedCrossRefGoogle Scholar
  18. 18.
    Wilcox WR, Oliveria JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93(2):112–128PubMedCrossRefGoogle Scholar
  19. 19.
    Ramaswami U, Whybra C, Parini R et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95(1):86–92PubMedCrossRefGoogle Scholar
  20. 20.
    Hopkin RJ, Zarate AY (2008) Fabry disease. Lancet 372:1427–1435PubMedCrossRefGoogle Scholar
  21. 21.
    Whybra C, Baehner F, Baron K (2006) Measurement of disease severity and progression in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis Ltd, Oxford, pp 315–322Google Scholar
  22. 22.
    Orteu C, Janssen T, Lidove O et al (2007) Fabry disease and the skin: data from the Fabry outcome Survey. Br J Dermatol 157:331–337PubMedCrossRefGoogle Scholar
  23. 23.
    Sodi A, Ioannidis AS, Mehta A et al (2007) Ocular manifestations of Fabry disease: data from the Fabry Outcome Survey. Brit J Ophthal 91(2):210–214PubMedCrossRefGoogle Scholar
  24. 24.
    Hegemann S, Hajioff D, Conti G et al (2006) Hearing loss in Fabry disease: data from the Fabry Outcome Survey (FOS). Europ J Clin Invest 36(9):654–662PubMedCrossRefGoogle Scholar
  25. 25.
    Hoffman B, Schwarz M, Mehta A et al (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5(12):1447–1453CrossRefGoogle Scholar
  26. 26.
    Mehta A, Beck M, Sunder-Plassmann G (eds) (2006) Fabry disease, perspectives from 5 years of FOS. Oxford Pharmagenesis, Oxford, p 427Google Scholar
  27. 27.
    Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson Fabry Disease: results from the International Fabry Outcome Survey. Europ Heart J 28:228–235CrossRefGoogle Scholar
  28. 28.
    Schwarting A, Dehout F, Feriozzi S et al (2006) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66:77–84PubMedGoogle Scholar
  29. 29.
    Mehta A, Beck M, Elliott P et al (2009) Evidence of benefit of 5 years of enzyme replacement therapy with agalsidase alpha in patients with Fabry disease – A report from the Fabry outcome survey (FOS). Lancet 374:1986–1996PubMedCrossRefGoogle Scholar
  30. 30.
    Sims K, Politei J, Basikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40(3):788–794PubMedCrossRefGoogle Scholar
  31. 31.
    Mehta A, Ginsberg L, Investigators FOS (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 94(447):24–27, discussion 9–10PubMedCrossRefGoogle Scholar
  32. 32.
    Cox-Brinkman J, Vedder A, Hollak C et al (2007) Three dimensional face shape in Fabry disease. Europ J Human Genet 15(5):535–542CrossRefGoogle Scholar
  33. 33.
    Brown LK, Miller A, Bhuptani A et al (1997) Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 155(3):1004–1010PubMedGoogle Scholar
  34. 34.
    Magage S, Lubanda JC, Susa Z et al (2007) Natural history of the respiratory involvement in Anderson – Fabry disease. J Inherit Metab Dis 30(5):790–799PubMedCrossRefGoogle Scholar
  35. 35.
    Lidove O, Ramaswami U, Jaussaud R et al (2006) Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract 60(9):1053–1059PubMedCrossRefGoogle Scholar
  36. 36.
    Hauser AC, Gessl A, Lorenz M et al (2005) High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease. J Inherit Metab Dis 28(5):715–722PubMedCrossRefGoogle Scholar
  37. 37.
    Germain DP, Benistan K, Boutouyrie P et al (2005) Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 68(1):93–95PubMedCrossRefGoogle Scholar
  38. 38.
    Cybulla M, Kleber M, Walter KN et al (2006) Is Fabry disease associated with leukaemia? Br J Haematol 135(2):264–265PubMedCrossRefGoogle Scholar
  39. 39.
    Papaxanthos-Roche A, Deminiere C, Bauduer F et al (2007) Azoospermia as a new feature of Fabry disease. Fertil Steril 88(1):212.e15–212.e18CrossRefGoogle Scholar
  40. 40.
    Mehta A, Hughes DA Fabry disease. Gene reviews at GeneTests: medical genetics information resource [database online]. Copyright, University of Washington, Seattle (updated Feb 2008). Available at http://www.genetests.org
  41. 41.
    Cole AL, Lee PJ, Hughes DA et al (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30(6):943–951PubMedCrossRefGoogle Scholar
  42. 42.
    Schaefer E, Mehta A, Gal A (2005) Genotype and phenotype in Fabry Disease: analysis of the Fabry Outcome Survey. Acta Paediactrica 94(Suppl 447):87–92CrossRefGoogle Scholar
  43. 43.
    Schiffmann R, Warnock DG, Banikazemi M et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24(7):2102–2111PubMedCrossRefGoogle Scholar
  44. 44.
    Mehta A, Clarke J, Giugliani R et al (2009) Natural Course of Fabry disease: changing pattern of causes of death in FOS, the Fabry Outcome Survey. J. Med Genet 46(8):548–552PubMedCrossRefGoogle Scholar
  45. 45.
    Waldek S, Patel MR, Banikazemi M, Lemay I, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11(11):1–7CrossRefGoogle Scholar
  46. 46.
    Mehta A, Lewis S, Laverey C (2003) Treatment of lysosomal storage disorders (Editorial). Brit Med J 327:462–463PubMedCrossRefGoogle Scholar

Copyright information

© Springer Netherlands 2010

Authors and Affiliations

  1. 1.Department of Haematology, Royal Free Hospital, University College London School of MedicineLondonUK

Personalised recommendations